June 25, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Arvinas (Nasdaq:ARVN), a pharmaceutical company inventing the famous proprietary PROTAC® protein degraders.
June 16, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Dr. Yonghong Wan’s lab at McMaster University at Hamilton Ontario Canada.
May 10, 2021 | BALTIMORE – Complete Omics’ Clinical Proteomics team announced a collaboration with Professor Zhenghe Wang and his team from the Case Western Researve University on a series of clinical proteomics projects focusing on leveraging our Complete360 targete detection pipeline for biological discoveries.
Our clinical proteomics pipeline enabling personalized cancer therapeutics, reported by numerous media
Complete Omics’ Clinical Proteomics team is proud to share with you the recent media coverage of our efforts in paving the way for the ultimate personalized cancer therapeutics. Our efforts toward achieving this ultimate goal of cancer treatment were reported by GenomeWeb, The Scientist, Precision Oncology News, News Wise, Fierce Biotech, etc. One of our clinical proteomics pipelines can help identify personalized cancer neoantigens that can be further targeted by a variety of therapeutic approaches, such as mRNA cancer vaccine, therapeutic peptide injection, engineering cell therapy, and here two bispecific antibody approaches.